Molecular Profiling is Absolutely Worthwhile in Poorly Differentiated Lung Carcinoma
Yes, comprehensive molecular profiling should be performed in this patient with poorly differentiated M1a lung carcinoma, regardless of the degree of differentiation. The histologic grade does not preclude the presence of actionable driver mutations that could fundamentally change treatment approach and outcomes.
Why Differentiation Status Does Not Matter
The most recent NCCN guidelines (2024) are unequivocal: molecular testing for somatic, disease-associated oncogenic driver mutations should be conducted as part of broad molecular profiling in all patients with advanced or metastatic NSCLC 1. This recommendation applies to:
- All non-squamous NSCLC (adenocarcinoma, large cell carcinoma, NSCLC-NOS)
- Even squamous cell carcinoma (where actionable mutations occur in 2-10% of cases) 1
- No exclusions based on degree of differentiation
The 2021 NCCN guidelines explicitly state that molecular testing should be considered in all patients with metastatic NSCLC, and that "characteristics—such as smoking status, small biopsy specimens, and mixed histology—should no longer be used when considering whether to perform biomarker testing" 2. Poorly differentiated histology is simply not a contraindication.
What Should Be Tested
Comprehensive panel-based testing (preferably NGS) should include at minimum 1:
- EGFR mutations (Category 1)
- ALK rearrangements (Category 1)
- ROS1 rearrangements
- BRAF V600E mutations
- NTRK1/2/3 fusions
- METex14 skipping mutations
- RET rearrangements
- ERBB2 (HER2) alterations
- KRAS mutations (including G12C)
The 2018 CAP/IASLC/AMP molecular testing guideline reinforces that adequate tissue should be obtained for both histological diagnosis and molecular testing, and that testing should extend beyond FDA-approved targets to include alterations with compelling evidence from clinical trials 3.
Real-World Evidence Supporting Testing in Poorly Differentiated Tumors
A compelling case report demonstrates exactly why this matters: a patient with a poorly differentiated malignant neoplasm lacking typical lung markers underwent comprehensive genomic profiling that identified an EML4-ALK rearrangement, leading to front-line crizotinib treatment with major sustained response 4. Without molecular profiling, this patient would have been treated empirically with chemotherapy and missed a highly effective targeted therapy.
Additional research shows that comprehensive genomic profiling identifies druggable alterations in 25-26% of NSCLC patients, including 20% of those with negative results on prior multiplex testing 5. Among 6,832 consecutive NSCLC cases, 71% harbored at least one actionable genomic alteration 6.
Practical Implementation
Testing can be performed on 1:
- Tissue biopsy (preferred when adequate)
- Plasma cell-free DNA (cfDNA) testing
- Concurrent tissue and plasma testing (improves turnaround time)
If tissue is limited: Plasma testing can "rule in" targetable mutations when tissue is insufficient 3. Negative plasma results should prompt tissue testing if possible.
Timing consideration: If urgent treatment initiation is required, start platinum-based chemotherapy alone (hold immunotherapy for one cycle) while awaiting molecular results 1. Retrospective data show that availability of molecular testing before treatment initiation is associated with longer overall survival 1.
Critical Pitfall to Avoid
Do not assume poorly differentiated histology means no actionable mutations exist. The 2018 molecular testing guideline specifically addresses that morphology-based interpretation may be insufficient in poorly differentiated tumors or limited biopsy samples, making immunohistochemistry panels and molecular profiling even more important 3.
The Bottom Line
Perform comprehensive molecular profiling now. The degree of differentiation is irrelevant to the presence of targetable driver mutations. If an actionable mutation is found (which occurs in the majority of cases), targeted therapy typically offers superior response rates, better tolerability, and improved outcomes compared to empiric chemotherapy 2. The potential to identify a driver mutation that could transform this patient's treatment and prognosis far outweighs any concerns about tissue adequacy or histologic grade.